Study of Molecular Response Adaptive Immuno-Chemotherpay in Patients With NSCLC
Condition: Non-Small Cell Lung Cancer Intervention: Drug: Pembrolizumab Sponsors: Canadian Cancer Trials Group; Cancer Research Institute, New York City; Personal Genome Diagnostics (PGDx); Mark Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials